CD274 and neoplasm: Thus, these patients possibly have a better response to immune checkpoint inhibitors like PD-1/PD-L1 inhibitors, as these drugs are able to disrupt the binding of PD-1/PD-L1 with restore T cell-mediated tumour attack (24, 25).